Vascular Biogenics (NASDAQ:VBLT) Trading Up 8.6%

Shares of Vascular Biogenics Ltd (NASDAQ:VBLT) were up 8.6% during trading on Thursday . The company traded as high as $1.28 and last traded at $1.26. Approximately 115,736 shares changed hands during trading, a decline of 5% from the average daily volume of 121,978 shares. The stock had previously closed at $1.16.

A number of analysts recently commented on VBLT shares. Zacks Investment Research upgraded shares of Vascular Biogenics from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research note on Thursday, May 16th. HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of Vascular Biogenics in a research note on Thursday, May 16th. Chardan Capital restated a “hold” rating and set a $3.00 price target on shares of Vascular Biogenics in a research note on Thursday, May 16th. CIBC started coverage on shares of Vascular Biogenics in a research note on Thursday. They set an “outperform” rating on the stock. Finally, Oppenheimer started coverage on shares of Vascular Biogenics in a research note on Thursday. They set an “outperform” rating and a $2.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. Vascular Biogenics has a consensus rating of “Hold” and a consensus target price of $2.38.

The stock has a fifty day moving average of $1.25. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.35 and a current ratio of 8.35.

Vascular Biogenics (NASDAQ:VBLT) last posted its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.06). The firm had revenue of $0.22 million for the quarter, compared to the consensus estimate of $2.30 million. Vascular Biogenics had a negative return on equity of 31.69% and a negative net margin of 2,724.02%. Equities analysts predict that Vascular Biogenics Ltd will post -0.52 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of VBLT. Athena Capital Advisors LLC bought a new stake in Vascular Biogenics during the 1st quarter worth approximately $25,000. Menta Capital LLC bought a new stake in Vascular Biogenics during the 1st quarter worth approximately $35,000. First Republic Investment Management Inc. increased its holdings in Vascular Biogenics by 7.4% during the 1st quarter. First Republic Investment Management Inc. now owns 145,000 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 10,000 shares during the period. Finally, RBF Capital LLC bought a new stake in Vascular Biogenics during the 4th quarter worth approximately $353,000. 6.85% of the stock is currently owned by institutional investors and hedge funds.

About Vascular Biogenics (NASDAQ:VBLT)

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Recommended Story: Day Trading

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.